RBC Capital analyst Shagun Singh lowered the firm’s price target on Outset Medical (OM) to $17 from $22 and keeps a Sector Perform rating on the shares. The company delivered a 4% revenue miss and lowered 2025 guide by 5% due to delayed closing of several large deals forecasted for the second half of 2025 and potential impact from the Q4 departure of Head of Sales, the analyst tells investors in a research note. Outset Q4 guide implies accelerating sequential declines that may prove conservative however, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM: